English
- English
- 中文
Core Architecture
Core Architecture
PanMediso
PanMediso (referred to as "PM UK") is composed of an internationally renowned team with over 20 years of isotope research and development experience, led by Fellows of the Royal Academy of Engineering and the Royal Society in the UK, as well as the Chief Scientist of the UK Government's Nuclear Fuels and the Canadian Nuclear Laboratory. The company possesses globally leading production processes for isotopes such as Ac-225 and diagnostic medical isotope Ge-68. Dedicated to optimizing the treatment effectiveness of cancer and other life-threatening diseases, PanMediso has mastered a process for high-purity bulk production of Ac-225 and has achieved laboratory-scale production. The company aims to become the world's first isotope production enterprise to achieve GMP-level supply by 2025.
Possesses specialized knowledge and extensive experience in isotope research and production.
Committed to improving the treatment effectiveness of cancer and other life-threatening diseases.
By assembling isotope drugs and collaborating with downstream pharmaceutical companies, we ensure the safe and timely supply of isotopes for clinical trials and delivery to patients worldwide.
Possesses specialized knowledge and extensive experience in isotope research and production.
Committed to improving the treatment effectiveness of cancer and other life-threatening diseases.
By assembling isotope drugs and collaborating with downstream pharmaceutical companies, we ensure the safe and timely supply of isotopes for clinical trials and delivery to patients worldwide.
Email: pchl@pamedicholdings.com
Address: Room 406, Building C, Hetao Innovation Center No. 1 Honghua
Road, Fubao Subdistrict Futian District, Shenzhen, China
Copyright@2025 PanMediso
